A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

July 8, 2024

Study Completion Date

August 8, 2024

Conditions
Crohn Disease
Interventions
DRUG

BI 706321

One dose of 8 mg as tablets orally once per day in the morning

DRUG

Ustekinumab

A single intravenous infusion of 260 mg (body weight ≤55 kg), 390 mg (body weight 55-85 kg), or 520 mg (body weight \>85 kg) was administered on Day 0, followed by subcutaneous injection of 90 mg every 8 weeks.

DRUG

Placebo

One dose of placebo matching BI 706321 as tablets orally once per day in the morning

Trial Locations (49)

1000

Brussels - UNIV St-Pierre, Brussels

1033

Clinexpert Kft., Budapest

3000

UZ Leuven, Leuven

3200

Bugat Pal Hospital, Gyongyos, Gyöngyös

4000

Centre Hospitalier Universitaire de Liège, Liège

4032

University of Debrecen Clinical Centre, Debrecen

7000

UNIV Ambroise Paré, Mons

9000

AZ Maria Middelares, Ghent

AZ Sint-Lucas - Campus Sint Lucas, Ghent

9100

Aalborg Sygehus Syd, Aalborg

14004

payee-Hospital Universitario Reina Sofia. Cordoba, Córdoba

20097

IRCCS Policlinico San Donato, San Donato Milanese (MI)

20122

IRCCS Fondazione Ospedale Maggiore, Milan

20132

IRCCS San Raffaele, Milan

27100

Fondazione IRCCS Policlinico S. Matteo, Pavia

27834

Carolina Digestive Diseases, Greenville

28006

Hospital La Princesa, Madrid

32825

Advanced Research Institute, Inc., Orlando

33016

Sweet Hope Research Specialty Inc, Hialeah

34452

Nature Coast Clinical Research, Inverness

34741

I.H.S Health, LLC, Kissimmee

37024

Osp.Sacro Cuore-Don Calabria, Negrar (VR)

41071

Hospital Virgen Macarena, Seville

46026

Hospital Politècnic La Fe, Valencia

46202

Indiana University, Indianapolis

49519

Gastroenterology Associates of Western Michigan, Wyoming

50002

Hepato-Gastroenterologie HK, s.r.o., Hradec Králové

60612

Rush University Medical Center, Chicago

64068

BVL Clinical Research, Liberty

76092

GI Alliance, Southlake

77030

Houston Methodist Hospital, Houston

78229

Southern Star Research Institute, LLC, San Antonio

84132

University of Utah Health Sciences Center, Salt Lake City

85231

NZOZ Medical Center KERmed, Bydgoszcz

88100

Policlinico Universitario Mater Domini, Universita di Catanzaro, Catanzaro

89081

Universitätsklinikum Ulm, Ulm

91324

California Medical Research Associates Inc., Northridge

98195

University of Washington, Seattle

708 52

University Hospital Ostrava, Ostrava

00133

Az. Ospedaliera Universitaria Polic.Tor Vergata, Roma

6525 GA

Radboud Universitair Medisch Centrum, Nijmegen

5022 GC

St Elisabeth Ziekenhuis, Tilburg

44-190

Indywidualna Specjalistyczna Praktyka Lekarska Maciej Zymla, Knurów

95-054

Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska sp. j., Ksawerów

20-582

Healthcare Center Gastromed - SCANMED GROUP, Lublin

71-434

Twoja Przychodnia-Szczecinskie Centrum Medyczne, Szczecin

02-507

National Medical Institute MSWiA, Warsaw

08208

CEIC Corporacio Sanitaria Parc Taulí, Sabadell

L7 8XP

Royal Liverpool University Hospital, Liverpool

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04978493 - A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease | Biotech Hunter | Biotech Hunter